https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32873 Wed 19 Jan 2022 15:17:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45683 3 months ago, who had completed formal rehabilitation and had no significant cognitive impairment. Experimental group received botulinum toxin-A plus evidence-based movement training while the control group received botulinum toxin-A plus a handout of exercises. Primary outcomes were goal attainment (Goal Attainment Scaling) and upper limb activity (Box and Block Test) at 3 months (end of intervention). Secondary outcomes were spasticity, range of motion, strength, pain, burden of care, and health-related quality of life. Results: In terms of goal attainment, the experimental group scored the same (mean difference, 2 T-score [95% CI, −2 to 7]) as the control group on the Goal Attainment Scale. In terms of upper limb activity, by 3 months the experimental group moved blocks at the same speed (mean difference, 0.00 blocks/s [95% CI, −0.02 to 0.01]) as the control group on the Box and Block Test. There were no differences between groups on any secondary outcome except strength, in favor of the experimental group (mean difference, 1.4 kg [95% CI, 0.2–2.7]). Conclusions: Findings suggest that additional intensive upper limb rehabilitation following botulinum toxin-A in chronic stroke survivors with a disabled upper limb is not effective. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: ACTRN12615000616572. (Stroke. 2020;51:556-562. DOI: 10.1161/STROKEAHA.119.027602.)]]> Tue 21 Mar 2023 17:56:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44765 Mon 24 Oct 2022 08:49:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41055 Mon 08 Aug 2022 14:57:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51414 Mon 04 Sep 2023 14:52:01 AEST ]]>